APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pan-cancer Genomic Profiling

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pan-cancer Genomic Profiling Market Analysis and Forecast 2026-2032

Report ID 174522040512 August 2026181 pages

Choose your research edition.

Industry ResearchPan-cancer Genomic Profiling Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Pan-cancer Genomic Profiling Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Pan-cancer Genomic Profiling Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pan-cancer Genomic Profiling Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Pan-cancer Genomic Profiling Market Analysis and Forecast 2026-2032181 pages · $4,950 USD

Market perspective

The global Pan-cancer Genomic Profiling market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pan-cancer Genomic Profiling is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pan-cancer Genomic Profiling is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pan-cancer Genomic Profiling is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pan-cancer Genomic Profiling is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pan-cancer Genomic Profiling include Tempus AI, Labcorp, NeoGenomics, Exact Sciences, Personalis, Illumina, Thermo Fisher Scientific, QIAGEN and Agilent Technologies, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pan-cancer Genomic Profiling, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pan-cancer Genomic Profiling, also provides the revenue of main regions and countries. Of the upcoming market potential for Pan-cancer Genomic Profiling, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pan-cancer Genomic Profiling revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pan-cancer Genomic Profiling market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pan-cancer Genomic Profiling revenue, projected growth trends, production technology, application and end-user industry.

Pan-cancer Genomic Profiling Segment by Company

Tempus AI

Labcorp

NeoGenomics

Exact Sciences

Personalis

Illumina

Thermo Fisher Scientific

QIAGEN

Agilent Technologies

SOPHiA GENETICS

Sysmex

Burning Rock Biotech

Genetron Health

Geneseeq

BGI Genomics

Amoy Diagnostics

Roche

Guardant Health

Caris Life Sciences

Pan-cancer Genomic Profiling Segment by Type

Tissue-based Profiling

Liquid Biopsy Profiling

Other

Pan-cancer Genomic Profiling Segment by Application

Hospitals and Cancer Centers

Independent Clinical Laboratories

Pharmaceutical and Biotechnology Companies

Other

Pan-cancer Genomic Profiling Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pan-cancer Genomic Profiling market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pan-cancer Genomic Profiling and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pan-cancer Genomic Profiling.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pan-cancer Genomic Profiling in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pan-cancer Genomic Profiling company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pan-cancer Genomic Profiling revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pan-cancer Genomic Profiling Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tissue-based Profiling Major Player Table 3. Liquid Biopsy Profiling Major Player Table 4. Other Major Player Table 5. Global Pan-cancer Genomic Profiling Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals and Cancer Centers Major Player Table 7. Independent Clinical Laboratories Major Player Table 8. Pharmaceutical and Biotechnology Companies Major Player Table 9. Other Major Player Table 10. Pan-cancer Genomic Profiling Industry Trends Table 11. Pan-cancer Genomic Profiling Industry Drivers Table 12. Pan-cancer Genomic Profiling Industry Opportunities and Challenges Table 13. Pan-cancer Genomic Profiling Industry Restraints Table 14. Global Pan-cancer Genomic Profiling Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Pan-cancer Genomic Profiling Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Pan-cancer Genomic Profiling Market Share by Region (2021-2026) Table 17. Global Pan-cancer Genomic Profiling Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Pan-cancer Genomic Profiling Market Share by Region (2027-2032) Table 19. Global Pan-cancer Genomic Profiling Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Pan-cancer Genomic Profiling Revenue Market Share by Players (2021-2026) Table 21. Global Pan-cancer Genomic Profiling Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Pan-cancer Genomic Profiling Key Players Headquarters & Area Served Table 23. Global Pan-cancer Genomic Profiling Players, Product Type & Application Table 24. Global Pan-cancer Genomic Profiling Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Pan-cancer Genomic Profiling by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Pan-cancer Genomic Profiling Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pan-cancer Genomic Profiling Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Pan-cancer Genomic Profiling Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Pan-cancer Genomic Profiling Revenue Market Share by Type (2021-2026) Table 31. Global Pan-cancer Genomic Profiling Revenue Market Share by Type (2027-2032) Table 32. Global Pan-cancer Genomic Profiling Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pan-cancer Genomic Profiling Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Pan-cancer Genomic Profiling Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Pan-cancer Genomic Profiling Revenue Market Share by Application (2021-2026) Table 36. Global Pan-cancer Genomic Profiling Revenue Market Share by Application (2027-2032) Table 37. Tempus AI Company Information Table 38. Tempus AI Business Overview Table 39. Tempus AI Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Tempus AI Pan-cancer Genomic Profiling Product Portfolio Table 41. Tempus AI Recent Development Table 42. Labcorp Company Information Table 43. Labcorp Business Overview Table 44. Labcorp Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Labcorp Pan-cancer Genomic Profiling Product Portfolio Table 46. Labcorp Recent Development Table 47. NeoGenomics Company Information Table 48. NeoGenomics Business Overview Table 49. NeoGenomics Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. NeoGenomics Pan-cancer Genomic Profiling Product Portfolio Table 51. NeoGenomics Recent Development Table 52. Exact Sciences Company Information Table 53. Exact Sciences Business Overview Table 54. Exact Sciences Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Exact Sciences Pan-cancer Genomic Profiling Product Portfolio Table 56. Exact Sciences Recent Development Table 57. Personalis Company Information Table 58. Personalis Business Overview Table 59. Personalis Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Personalis Pan-cancer Genomic Profiling Product Portfolio Table 61. Personalis Recent Development Table 62. Illumina Company Information Table 63. Illumina Business Overview Table 64. Illumina Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Illumina Pan-cancer Genomic Profiling Product Portfolio Table 66. Illumina Recent Development Table 67. Thermo Fisher Scientific Company Information Table 68. Thermo Fisher Scientific Business Overview Table 69. Thermo Fisher Scientific Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Thermo Fisher Scientific Pan-cancer Genomic Profiling Product Portfolio Table 71. Thermo Fisher Scientific Recent Development Table 72. QIAGEN Company Information Table 73. QIAGEN Business Overview Table 74. QIAGEN Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. QIAGEN Pan-cancer Genomic Profiling Product Portfolio Table 76. QIAGEN Recent Development Table 77. Agilent Technologies Company Information Table 78. Agilent Technologies Business Overview Table 79. Agilent Technologies Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Agilent Technologies Pan-cancer Genomic Profiling Product Portfolio Table 81. Agilent Technologies Recent Development Table 82. SOPHiA GENETICS Company Information Table 83. SOPHiA GENETICS Business Overview Table 84. SOPHiA GENETICS Pan-cancer Genomic Profiling Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. SOPHiA GENETICS Pan-cancer Genomic Profiling Product Portfolio Table 86. SOPHiA GENETICS Recent Development Table 87. Sysmex Company Information Table 88. Sysmex Business Overview Table 89. Sysmex Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Sysmex Pan-cancer Genomic Profiling Product Portfolio Table 91. Sysmex Recent Development Table 92. Burning Rock Biotech Company Information Table 93. Burning Rock Biotech Business Overview Table 94. Burning Rock Biotech Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Burning Rock Biotech Pan-cancer Genomic Profiling Product Portfolio Table 96. Burning Rock Biotech Recent Development Table 97. Genetron Health Company Information Table 98. Genetron Health Business Overview Table 99. Genetron Health Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Genetron Health Pan-cancer Genomic Profiling Product Portfolio Table 101. Genetron Health Recent Development Table 102. Geneseeq Company Information Table 103. Geneseeq Business Overview Table 104. Geneseeq Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Geneseeq Pan-cancer Genomic Profiling Product Portfolio Table 106. Geneseeq Recent Development Table 107. BGI Genomics Company Information Table 108. BGI Genomics Business Overview Table 109. BGI Genomics Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. BGI Genomics Pan-cancer Genomic Profiling Product Portfolio Table 111. BGI Genomics Recent Development Table 112. Amoy Diagnostics Company Information Table 113. Amoy Diagnostics Business Overview Table 114. Amoy Diagnostics Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Amoy Diagnostics Pan-cancer Genomic Profiling Product Portfolio Table 116. Amoy Diagnostics Recent Development Table 117. Roche Company Information Table 118. Roche Business Overview Table 119. Roche Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Roche Pan-cancer Genomic Profiling Product Portfolio Table 121. Roche Recent Development Table 122. Guardant Health Company Information Table 123. Guardant Health Business Overview Table 124. Guardant Health Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Guardant Health Pan-cancer Genomic Profiling Product Portfolio Table 126. Guardant Health Recent Development Table 127. Caris Life Sciences Company Information Table 128. Caris Life Sciences Business Overview Table 129. Caris Life Sciences Pan-cancer Genomic Profiling Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Caris Life Sciences Pan-cancer Genomic Profiling Product Portfolio Table 131. Caris Life Sciences Recent Development Table 132. North America Pan-cancer Genomic Profiling Revenue by Type (2021-2026) & (US$ Million) Table 133. North America Pan-cancer Genomic Profiling Revenue by Type (2027-2032) & (US$ Million) Table 134. North America Pan-cancer Genomic Profiling Revenue by Application (2021-2026) & (US$ Million) Table 135. North America Pan-cancer Genomic Profiling Revenue by Application (2027-2032) & (US$ Million) Table 136. North America Pan-cancer Genomic Profiling Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Pan-cancer Genomic Profiling Revenue by Country (2021-2026) & (US$ Million) Table 138. North America Pan-cancer Genomic Profiling Revenue by Country (US$ Million) & (2027-2032) Table 139. Europe Pan-cancer Genomic Profiling Revenue by Type (2021-2026) & (US$ Million) Table 140. Europe Pan-cancer Genomic Profiling Revenue by Type (2027-2032) & (US$ Million) Table 141. Europe Pan-cancer Genomic Profiling Revenue by Application (2021-2026) & (US$ Million) Table 142. Europe Pan-cancer Genomic Profiling Revenue by Application (2027-2032) & (US$ Million) Table 143. Europe Pan-cancer Genomic Profiling Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Pan-cancer Genomic Profiling Revenue by Country (2021-2026) & (US$ Million) Table 145. Europe Pan-cancer Genomic Profiling Revenue by Country (US$ Million) & (2027-2032) Table 146. China Pan-cancer Genomic Profiling Revenue by Type (2021-2026) & (US$ Million) Table 147. China Pan-cancer Genomic Profiling Revenue by Type (2027-2032) & (US$ Million) Table 148. China Pan-cancer Genomic Profiling Revenue by Application (2021-2026) & (US$ Million) Table 149. China Pan-cancer Genomic Profiling Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia Pan-cancer Genomic Profiling Revenue by Type (2021-2026) & (US$ Million) Table 151. Asia Pan-cancer Genomic Profiling Revenue by Type (2027-2032) & (US$ Million) Table 152. Asia Pan-cancer Genomic Profiling Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia Pan-cancer Genomic Profiling Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Pan-cancer Genomic Profiling Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Asia Pan-cancer Genomic Profiling Revenue by Region (US$ Million) & (2021-2026) Table 156. Asia Pan-cancer Genomic Profiling Revenue by Region (US$ Million) & (2027-2032) Table 157. SAMEA Pan-cancer Genomic Profiling Revenue by Type (2021-2026) & (US$ Million) Table 158. SAMEA Pan-cancer Genomic Profiling Revenue by Type (2027-2032) & (US$ Million) Table 159. SAMEA Pan-cancer Genomic Profiling Revenue by Application (2021-2026) & (US$ Million) Table 160. SAMEA Pan-cancer Genomic Profiling Revenue by Application (2027-2032) & (US$ Million) Table 161. SAMEA Pan-cancer Genomic Profiling Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. SAMEA Pan-cancer Genomic Profiling Revenue by Country (2021-2026) & (US$ Million) Table 163. SAMEA Pan-cancer Genomic Profiling Revenue by Country (US$ Million) & (2027-2032) Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Pan-cancer Genomic Profiling Image Figure 2. Global Pan-cancer Genomic Profiling Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pan-cancer Genomic Profiling Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tissue-based Profiling Image Figure 5. Liquid Biopsy Profiling Image Figure 6. Other Image Figure 7. Global Pan-cancer Genomic Profiling Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Pan-cancer Genomic Profiling Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals and Cancer Centers Image Figure 10. Independent Clinical Laboratories Image Figure 11. Pharmaceutical and Biotechnology Companies Image Figure 12. Other Image Figure 13. Global Pan-cancer Genomic Profiling Market Size (US$ Million) & (2021-2032) Figure 14. Global Pan-cancer Genomic Profiling Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Pan-cancer Genomic Profiling Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Pan-cancer Genomic Profiling Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Pan-cancer Genomic Profiling Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pan-cancer Genomic Profiling Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pan-cancer Genomic Profiling Revenue Market Share by Type (2021-2032) Figure 21. Global Pan-cancer Genomic Profiling Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Pan-cancer Genomic Profiling Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Pan-cancer Genomic Profiling Revenue Market Share by Application (2021-2032) Figure 24. North America Pan-cancer Genomic Profiling Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032) Figure 26. North America Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032) Figure 27. North America Pan-cancer Genomic Profiling Revenue Share by Country (2021-2032) Figure 28. United States Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Pan-cancer Genomic Profiling Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032) Figure 33. Europe Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032) Figure 34. Europe Pan-cancer Genomic Profiling Revenue Share by Country (2021-2032) Figure 35. Germany Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Pan-cancer Genomic Profiling Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032) Figure 45. China Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032) Figure 46. Asia Pan-cancer Genomic Profiling Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032) Figure 48. Asia Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032) Figure 49. Asia Pan-cancer Genomic Profiling Revenue Share by Region (2021-2032) Figure 50. Japan Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Pan-cancer Genomic Profiling Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032) Figure 58. SAMEA Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032) Figure 59. SAMEA Pan-cancer Genomic Profiling Revenue Share by Country (2021-2032) Figure 60. Brazil Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Pan-cancer Genomic Profiling Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Tissue-based Profiling
  • Liquid Biopsy Profiling
  • Other
Applications
  • Hospitals and Cancer Centers
  • Independent Clinical Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Other
Companies covered
  • Tempus AI
  • Labcorp
  • NeoGenomics
  • Exact Sciences
  • Personalis
  • Illumina
  • Thermo Fisher Scientific
  • QIAGEN
  • Agilent Technologies
  • SOPHiA GENETICS
  • Sysmex
  • Burning Rock Biotech
  • Genetron Health
  • Geneseeq
  • BGI Genomics
  • Amoy Diagnostics
  • Roche
  • Guardant Health
  • Caris Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pan-cancer Genomic Profiling Market by Type
  3. 1.2.1 Global Pan-cancer Genomic Profiling Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tissue-based Profiling
  5. 1.2.3 Liquid Biopsy Profiling
  6. 1.2.4 Other
  7. 1.3 Pan-cancer Genomic Profiling Market by Application
  8. 1.3.1 Global Pan-cancer Genomic Profiling Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals and Cancer Centers
  10. 1.3.3 Independent Clinical Laboratories
  11. 1.3.4 Pharmaceutical and Biotechnology Companies
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Pan-cancer Genomic Profiling Market Dynamics
  1. 2.1 Pan-cancer Genomic Profiling Industry Trends
  2. 2.2 Pan-cancer Genomic Profiling Industry Drivers
  3. 2.3 Pan-cancer Genomic Profiling Industry Opportunities and Challenges
  4. 2.4 Pan-cancer Genomic Profiling Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pan-cancer Genomic Profiling Market Perspective (2021-2032)
  2. 3.2 Global Pan-cancer Genomic Profiling Growth Trends by Region
  3. 3.2.1 Global Pan-cancer Genomic Profiling Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pan-cancer Genomic Profiling Market Size by Region (2021-2026)
  5. 3.2.3 Global Pan-cancer Genomic Profiling Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pan-cancer Genomic Profiling Revenue by Players
  2. 4.1.1 Global Pan-cancer Genomic Profiling Revenue by Players (2021-2026)
  3. 4.1.2 Global Pan-cancer Genomic Profiling Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pan-cancer Genomic Profiling Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pan-cancer Genomic Profiling Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pan-cancer Genomic Profiling Key Players Headquarters & Area Served
  7. 4.4 Global Pan-cancer Genomic Profiling Players, Product Type & Application
  8. 4.5 Global Pan-cancer Genomic Profiling Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pan-cancer Genomic Profiling Market CR5 and HHI
  11. 4.6.3 2025 Pan-cancer Genomic Profiling Tier 1, Tier 2, and Tier 3
5 Pan-cancer Genomic Profiling Market Size by Type
  1. 5.1 Global Pan-cancer Genomic Profiling Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pan-cancer Genomic Profiling Revenue by Type (2021-2032)
  3. 5.3 Global Pan-cancer Genomic Profiling Revenue Market Share by Type (2021-2032)
6 Pan-cancer Genomic Profiling Market Size by Application
  1. 6.1 Global Pan-cancer Genomic Profiling Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pan-cancer Genomic Profiling Revenue by Application (2021-2032)
  3. 6.3 Global Pan-cancer Genomic Profiling Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Tempus AI
  2. 7.1.1 Tempus AI Company Information
  3. 7.1.2 Tempus AI Business Overview
  4. 7.1.3 Tempus AI Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Tempus AI Pan-cancer Genomic Profiling Product Portfolio
  6. 7.1.5 Tempus AI Recent Developments
  7. 7.2 Labcorp
  8. 7.2.1 Labcorp Company Information
  9. 7.2.2 Labcorp Business Overview
  10. 7.2.3 Labcorp Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Labcorp Pan-cancer Genomic Profiling Product Portfolio
  12. 7.2.5 Labcorp Recent Developments
  13. 7.3 NeoGenomics
  14. 7.3.1 NeoGenomics Company Information
  15. 7.3.2 NeoGenomics Business Overview
  16. 7.3.3 NeoGenomics Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  17. 7.3.4 NeoGenomics Pan-cancer Genomic Profiling Product Portfolio
  18. 7.3.5 NeoGenomics Recent Developments
  19. 7.4 Exact Sciences
  20. 7.4.1 Exact Sciences Company Information
  21. 7.4.2 Exact Sciences Business Overview
  22. 7.4.3 Exact Sciences Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Exact Sciences Pan-cancer Genomic Profiling Product Portfolio
  24. 7.4.5 Exact Sciences Recent Developments
  25. 7.5 Personalis
  26. 7.5.1 Personalis Company Information
  27. 7.5.2 Personalis Business Overview
  28. 7.5.3 Personalis Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Personalis Pan-cancer Genomic Profiling Product Portfolio
  30. 7.5.5 Personalis Recent Developments
  31. 7.6 Illumina
  32. 7.6.1 Illumina Company Information
  33. 7.6.2 Illumina Business Overview
  34. 7.6.3 Illumina Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Illumina Pan-cancer Genomic Profiling Product Portfolio
  36. 7.6.5 Illumina Recent Developments
  37. 7.7 Thermo Fisher Scientific
  38. 7.7.1 Thermo Fisher Scientific Company Information
  39. 7.7.2 Thermo Fisher Scientific Business Overview
  40. 7.7.3 Thermo Fisher Scientific Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Thermo Fisher Scientific Pan-cancer Genomic Profiling Product Portfolio
  42. 7.7.5 Thermo Fisher Scientific Recent Developments
  43. 7.8 QIAGEN
  44. 7.8.1 QIAGEN Company Information
  45. 7.8.2 QIAGEN Business Overview
  46. 7.8.3 QIAGEN Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  47. 7.8.4 QIAGEN Pan-cancer Genomic Profiling Product Portfolio
  48. 7.8.5 QIAGEN Recent Developments
  49. 7.9 Agilent Technologies
  50. 7.9.1 Agilent Technologies Company Information
  51. 7.9.2 Agilent Technologies Business Overview
  52. 7.9.3 Agilent Technologies Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Agilent Technologies Pan-cancer Genomic Profiling Product Portfolio
  54. 7.9.5 Agilent Technologies Recent Developments
  55. 7.10 SOPHiA GENETICS
  56. 7.10.1 SOPHiA GENETICS Company Information
  57. 7.10.2 SOPHiA GENETICS Business Overview
  58. 7.10.3 SOPHiA GENETICS Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  59. 7.10.4 SOPHiA GENETICS Pan-cancer Genomic Profiling Product Portfolio
  60. 7.10.5 SOPHiA GENETICS Recent Developments
  61. 7.11 Sysmex
  62. 7.11.1 Sysmex Company Information
  63. 7.11.2 Sysmex Business Overview
  64. 7.11.3 Sysmex Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sysmex Pan-cancer Genomic Profiling Product Portfolio
  66. 7.11.5 Sysmex Recent Developments
  67. 7.12 Burning Rock Biotech
  68. 7.12.1 Burning Rock Biotech Company Information
  69. 7.12.2 Burning Rock Biotech Business Overview
  70. 7.12.3 Burning Rock Biotech Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Burning Rock Biotech Pan-cancer Genomic Profiling Product Portfolio
  72. 7.12.5 Burning Rock Biotech Recent Developments
  73. 7.13 Genetron Health
  74. 7.13.1 Genetron Health Company Information
  75. 7.13.2 Genetron Health Business Overview
  76. 7.13.3 Genetron Health Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Genetron Health Pan-cancer Genomic Profiling Product Portfolio
  78. 7.13.5 Genetron Health Recent Developments
  79. 7.14 Geneseeq
  80. 7.14.1 Geneseeq Company Information
  81. 7.14.2 Geneseeq Business Overview
  82. 7.14.3 Geneseeq Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Geneseeq Pan-cancer Genomic Profiling Product Portfolio
  84. 7.14.5 Geneseeq Recent Developments
  85. 7.15 BGI Genomics
  86. 7.15.1 BGI Genomics Company Information
  87. 7.15.2 BGI Genomics Business Overview
  88. 7.15.3 BGI Genomics Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  89. 7.15.4 BGI Genomics Pan-cancer Genomic Profiling Product Portfolio
  90. 7.15.5 BGI Genomics Recent Developments
  91. 7.16 Amoy Diagnostics
  92. 7.16.1 Amoy Diagnostics Company Information
  93. 7.16.2 Amoy Diagnostics Business Overview
  94. 7.16.3 Amoy Diagnostics Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Amoy Diagnostics Pan-cancer Genomic Profiling Product Portfolio
  96. 7.16.5 Amoy Diagnostics Recent Developments
  97. 7.17 Roche
  98. 7.17.1 Roche Company Information
  99. 7.17.2 Roche Business Overview
  100. 7.17.3 Roche Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Roche Pan-cancer Genomic Profiling Product Portfolio
  102. 7.17.5 Roche Recent Developments
  103. 7.18 Guardant Health
  104. 7.18.1 Guardant Health Company Information
  105. 7.18.2 Guardant Health Business Overview
  106. 7.18.3 Guardant Health Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Guardant Health Pan-cancer Genomic Profiling Product Portfolio
  108. 7.18.5 Guardant Health Recent Developments
  109. 7.19 Caris Life Sciences
  110. 7.19.1 Caris Life Sciences Company Information
  111. 7.19.2 Caris Life Sciences Business Overview
  112. 7.19.3 Caris Life Sciences Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Caris Life Sciences Pan-cancer Genomic Profiling Product Portfolio
  114. 7.19.5 Caris Life Sciences Recent Developments
8 North America
  1. 8.1 North America Pan-cancer Genomic Profiling Revenue (2021-2032)
  2. 8.2 North America Pan-cancer Genomic Profiling Revenue by Type (2021-2032)
  3. 8.2.1 North America Pan-cancer Genomic Profiling Revenue by Type (2021-2026)
  4. 8.2.2 North America Pan-cancer Genomic Profiling Revenue by Type (2027-2032)
  5. 8.3 North America Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032)
  6. 8.4 North America Pan-cancer Genomic Profiling Revenue by Application (2021-2032)
  7. 8.4.1 North America Pan-cancer Genomic Profiling Revenue by Application (2021-2026)
  8. 8.4.2 North America Pan-cancer Genomic Profiling Revenue by Application (2027-2032)
  9. 8.5 North America Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032)
  10. 8.6 North America Pan-cancer Genomic Profiling Revenue by Country
  11. 8.6.1 North America Pan-cancer Genomic Profiling Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pan-cancer Genomic Profiling Revenue by Country (2021-2026)
  13. 8.6.3 North America Pan-cancer Genomic Profiling Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Pan-cancer Genomic Profiling Revenue (2021-2032)
  2. 9.2 Europe Pan-cancer Genomic Profiling Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pan-cancer Genomic Profiling Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pan-cancer Genomic Profiling Revenue by Type (2027-2032)
  5. 9.3 Europe Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pan-cancer Genomic Profiling Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pan-cancer Genomic Profiling Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pan-cancer Genomic Profiling Revenue by Application (2027-2032)
  9. 9.5 Europe Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pan-cancer Genomic Profiling Revenue by Country
  11. 9.6.1 Europe Pan-cancer Genomic Profiling Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pan-cancer Genomic Profiling Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pan-cancer Genomic Profiling Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Pan-cancer Genomic Profiling Revenue (2021-2032)
  2. 10.2 China Pan-cancer Genomic Profiling Revenue by Type (2021-2032)
  3. 10.2.1 China Pan-cancer Genomic Profiling Revenue by Type (2021-2026)
  4. 10.2.2 China Pan-cancer Genomic Profiling Revenue by Type (2027-2032)
  5. 10.3 China Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032)
  6. 10.4 China Pan-cancer Genomic Profiling Revenue by Application (2021-2032)
  7. 10.4.1 China Pan-cancer Genomic Profiling Revenue by Application (2021-2026)
  8. 10.4.2 China Pan-cancer Genomic Profiling Revenue by Application (2027-2032)
  9. 10.5 China Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pan-cancer Genomic Profiling Revenue (2021-2032)
  2. 11.2 Asia Pan-cancer Genomic Profiling Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pan-cancer Genomic Profiling Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pan-cancer Genomic Profiling Revenue by Type (2027-2032)
  5. 11.3 Asia Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pan-cancer Genomic Profiling Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pan-cancer Genomic Profiling Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pan-cancer Genomic Profiling Revenue by Application (2027-2032)
  9. 11.5 Asia Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pan-cancer Genomic Profiling Revenue by Country
  11. 11.6.1 Asia Pan-cancer Genomic Profiling Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pan-cancer Genomic Profiling Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pan-cancer Genomic Profiling Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pan-cancer Genomic Profiling Revenue (2021-2032)
  2. 12.2 SAMEA Pan-cancer Genomic Profiling Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pan-cancer Genomic Profiling Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pan-cancer Genomic Profiling Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pan-cancer Genomic Profiling Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pan-cancer Genomic Profiling Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pan-cancer Genomic Profiling Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pan-cancer Genomic Profiling Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pan-cancer Genomic Profiling Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pan-cancer Genomic Profiling Revenue by Country
  11. 12.6.1 SAMEA Pan-cancer Genomic Profiling Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pan-cancer Genomic Profiling Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pan-cancer Genomic Profiling Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst